title: Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.
abstract: Ninety-eight type 2 diabetic patients with hyperlipidaemia in stable metabolic control with diet alone (41) or diet plus hypoglycaemic agents (57) were divided into two groups: group 1 was put on treatment with slow release bezafibrate 400 mg a day, while group 2 was considered as control. In group 1, after 1 month of bezafibrate, serum triglycerides fell by 47% and cholesterol by 13%. HDL cholesterol showed a non-significant trend toward an increase. Fasting blood glucose significantly decreased by 6%, fructosamine and glycated haemoglobin by 5%. During OGTT, the area under the curve of both serum C-peptide and blood glucose showed a trend toward a decrease after bezafibrate. However, the difference did not reach statistical significance. Thirty-six patients continued the treatment with the drug for 4 months and 23 for 8 months, without further changes of the lipid pattern and glycaemic control. In the control group no significant variation of the lipid levels occurred and diabetic control slightly worsened during the study. Bezafibrate has been proved to be effective in the treatment of hyperlipidaemia in type 2 diabetic patients. The drug seems moreover to improve glycaemic control. The mechanism by which bezafibrate produces this latter effect remains to be elucidated, though an increase of peripheral insulin sensitivity might be suggested.
authors.affiliation: Institute of Internal Medicine and Medical Physiopathology, University of Milan, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Rovellini
authors.forename: D
authors.initials: D
authors.lastname: Sommariva
authors.forename: A
authors.initials: A
authors.lastname: Branchi
authors.forename: F
authors.initials: F
authors.lastname: Maraffi
authors.forename: C
authors.initials: C
authors.lastname: Montalto
authors.forename: R
authors.initials: R
authors.lastname: Gandini
authors.forename: A
authors.initials: A
authors.lastname: Fasoli
mesh_terms: D000368:Aged; D001629:Bezafibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000032:analysis*; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications*; D005260:Female; D019270:Fructosamine; D006454:Hemoglobins / Q000032:analysis; D006595:Hexosamines / Q000097:blood; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D006454:Hemoglobins; D006595:Hexosamines; D008055:Lipids; D008075:Lipoproteins, HDL; D014280:Triglycerides; D019270:Fructosamine; D002784:Cholesterol; D001629:Bezafibrate